3.80
+13.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immutep Ltd ADR
Its shares trade under the ticker IMMP. It has been listed since 17 April 2012. In the fiscal year to 30 June 2025, it reported revenue of $5.0m and a net loss of $61.4m. At that date it held total assets of $157.0m and shareholders' equity of $143.6m.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Apr 2012
- Employees
- 51
- Website
- immutep.com ↗
- Head office
- LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3, NSW 2000
- Incorporated in
- C3
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immutep Ltd ADR has a focused product pipeline targeting cancer and autoimmune diseases.
- The company has multiple clinical trials in various phases for different cancer types.
- Immutep has a lead product candidate, eftilagimod alfa, in development for multiple indications.
Weaknesses
- Immutep has a small employee count of 51, indicating limited operational capacity.
- The company is based in Sydney, which may limit access to major biotech hubs.
- Immutep's IPO was in 2012, suggesting a long development timeline for its products.
Opportunities
- The growing market for immunotherapies presents potential for Immutep's LAG-3 related therapies.
- Phase III trials for TACTI-004 could lead to significant commercial opportunities.
- Expanding clinical trials into additional cancer types could increase market reach.
Threats
- The biotechnology sector is highly competitive with many players developing similar therapies.
- Clinical trial failures could delay or halt product development.
- Regulatory hurdles may impact the approval and market entry of Immutep's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.